StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimers disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.
March 24, 2023
RegMed Investors’ (RMi) pre-open: good news, it’s Friday
March 23, 2023
RegMed Investors’ (RMi) closing bell: momentum interrupts sector’s share pricing bouncing luckily to the upside
March 23, 2023
RegMed Investors’ (RMi) pre-open: Bottom, bottom is it in sight?
March 22, 2023
RegMed Investors’ (RMi) closing bell: more push and pull-down share pricings
March 22, 2023
RegMed Investors’ (RMi) pre-open: What’s on tap?
March 21, 2023
RegMed Investors’ (RMi) closing bell: an upside after negative actions
March 20, 2023
RegMed Investors’ (RMi) closing bell: cell and gene therapy equities are back in the trenches with share pricing hunkering down
March 20, 2023
RegMed Investors’ (RMi) pre-open: still vulnerable and receptive to electronic trading nibbles and bites
March 17, 2023
RegMed Investors’ (RMi) closing bell: a second Black Swan event this week
March 16, 2023
RegMed Investors’ (RMi) closing bell: sector responds to being oversold reversing some declines
35 companies, 1 interpreter!
Insight, foresight and recommendation
StemCells (STEM) – On 5/31 StemCells announced plans to dissolve its operations following the failure of a clinical trial that was testing a treatment for spinal cord injury. STEM said it would assess options to "monetize its intellectual property" — which could mean a sale of the compounds it was developing and corresponding study data. But it said stockholders may receive no value. GONE
gone
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.